# EDGAR Filing Document

**Accession Number:** 0001595097
**File Stem:** 0001193125-25-277748
**Filing Date:** 2025-11
**Character Count:** 114369
**Document Hash:** 13dcdcf14ae1df8e09d800c6904b15d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-277748.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001193125-25-277748

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 73

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corbus Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001595097
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464348039
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37348
- **FILM NUMBER:** 251473448

**BUSINESS ADDRESS:**
- **STREET 1:** 500 RIVER RIDGE DRIVE
- **CITY:** NORWOOD
- **STATE:** MA
- **ZIP:** 02062
- **BUSINESS PHONE:** 617-963-0103

**MAIL ADDRESS:**
- **STREET 1:** 500 RIVER RIDGE DRIVE
- **CITY:** NORWOOD
- **STATE:** MA
- **ZIP:** 02062

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAV Acquisition Corp
- **DATE OF NAME CHANGE:** 20131220

?xml version='1.0' encoding='ASCII'? 10-Q

s

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM** 10-Q

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the quarterly period ended** **September 30,** 2025

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the transition period from________ to_________.**

**Commission File Number:**

001-37348

Corbus Pharmaceuticals Holdings, Inc.

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| Delaware | 46-4348039 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

---

| | |
|:---|:---|
| 500 River Ridge Drive<br>Norwood**,** MA | 02062 |
| **(Address of principal executive offices)** | **(Zip code)** |

---

**(**617**)** 963-0100

**(Registrant's telephone number, including area code)**

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report): **N/A**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.0001 per share | CRBP | The Nasdaq Capital Market  |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 7, 2025, 17,553,037 shares of the registrant's common stock, $0.0001 par value, were issued and outstanding.

------

**CORBUS PHARMACEUTICALS HOLDINGS, INC.**

**Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2025**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page**  |
| **PART I**  |  |
| **FINANCIAL INFORMATION**  |  |
| Item 1. [<u>Condensed Consolidated Financial Statements (unaudited)</u>](#item1_financial_statements) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024</u>](#condensed_consolidated_balance_sheets) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024</u>](#statements_of_operations_and_comp_loss) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statement of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024</u>](#statement_of_stockholders_equity) | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024</u>](#statements_of_cash_flows) | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Notes to Condensed Consolidated Financial Statements</u>](#notes_to_financial_statements) | 8 |
| Item 2. [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item2_mda) | 19 |
| Item 3. [<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#item3_quantitative_and_qualitative) | 26 |
| Item 4. [<u>Controls and Procedures</u>](#item4_controls_and_procedures) | 26 |
| **PART II**  |  |
| **OTHER INFORMATION**  |  |
| Item 1. [<u>Legal Proceedings</u>](#item1_legal_proceedings) | 27 |
| Item 1A. [<u>Risk Factors</u>](#item_1a_risk_factors) | 27 |
| Item 2. [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item2_unregistered_sales_equity) | 27 |
| Item 3. [<u>Defaults Upon Senior Securities</u>](#item_3_defaults_upon_senior_securities) | 27 |
| Item 4. [<u>Mine Safety Disclosures</u>](#item_4_mine_safety_disclosures) | 27 |
| Item 5. [<u>Other Information</u>](#item_5_other_information) | 27 |
| Item 6. [<u>Exhibits</u>](#item_6_exhibits) | 28 |
| [<u>Signatures</u>](#signatures) | 29 |

---

------

**PART I — FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**Corbus Pharmaceuticals Holdings, Inc.**

**Condensed Consolidated Balance Sheets** 

**(in thousands, except share and per share amounts)** 

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31, 2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $26983 | $17198 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | 76999 | 131864 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 285 | 285 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 3304 | 3629 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 107571 | 152976 |
| Restricted cash | 385 | 385 |
| Property and equipment, net | 201 | 385 |
| Operating lease right-of-use assets | 1357 | 2133 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $109514 | $155879 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $2740 | $4786 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 12578 | 5426 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current | 1742 | 1606 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 17060 | 11818 |
| Operating lease liabilities, noncurrent | 307 | 1633 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 17367 | 13451 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value; 300,000,000 shares authorized,<br>12,534,853 and 12,179,482 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 627024 | 619285 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (534875) | (476893) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss) gain | (3) | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 92147 | 142428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $109514 | $155879 |

---

See notes to the unaudited condensed consolidated financial statements.

------

**Corbus Pharmaceuticals Holdings, Inc.**

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

**(in thousands, except share and per share amounts)** 

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months<br>Ended September 30,** | **For the Three Months<br>Ended September 30,** | **For the Nine Months<br>Ended September 30,** | **For the Nine Months<br>Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | $20860 | $10808 | $51689 | $23435 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 3557 | 4697 | 11655 | 12681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 24417 | 15505 | 63344 | 36116 |
| Operating loss | (24417) | (15505) | (63344) | (36116) |
| Other income (expense), net: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and investment income, net | 1125 | 1903 | 4120 | 4531 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (381) |  | (1872) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income, net | (50) | 200 | 1242 | 2778 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income, net | 1075 | 1722 | 5362 | 5437 |
| Net loss | $(23342) | $(13783) | $(57982) | $(30679) |
| Net loss per share, basic and diluted | $(1.90) | $(1.15) | $(4.73) | $(2.92) |
| Weighted average number of common shares outstanding, basic and diluted | 12307298 | 12014700 | 12250315 | 10490981 |
| Comprehensive loss: |  |  |  |  |
| Net loss | $(23342) | $(13783) | $(57982) | $(30679) |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in unrealized gain (loss) on marketable debt securities | 36 | 595 | (38) | 208 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | 36 | 595 | (38) | 208 |
| Total comprehensive loss | $(23306) | $(13188) | $(58020) | $(30471) |

---

See notes to the unaudited condensed consolidated financial statements.

------

**Corbus Pharmaceuticals Holdings, Inc.**

**Condensed Consolidated Statements of Stockholders' Equity**

**(in thousands, except share amounts)** 

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended September 30, 2025** | **For the Three Months Ended September 30, 2025** | **For the Three Months Ended September 30, 2025** | **For the Three Months Ended September 30, 2025** | **For the Three Months Ended September 30, 2025** | **For the Three Months Ended September 30, 2025** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional<br>Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated<br>Other<br>Comprehensive**<br>**(Loss) Income** | **Total<br>Stockholders'**<br>**Equity** |
| Balance at June 30, 2025 | 12254069 | $1 | $622562 | $(511533) | $(39) | $110991 |
| Issuance of common stock, net of issuance costs | 272938 |  | 2880 |  |  | 2880 |
| Issuance of common stock upon vesting of restricted stock units | 7846 |  |  |  |  |  |
| Stock-based compensation expense |  |  | 1582 |  |  | 1582 |
| Change in unrealized gain (loss) on marketable debt securities |  |  |  |  | 36 | 36 |
| Net loss |  |  |  | (23342) |  | (23342) |
| Balance at September 30, 2025 | 12534853 | $1 | $627024 | $(534875) | $(3) | $92147 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended September 30, 2024** | **For the Three Months Ended September 30, 2024** | **For the Three Months Ended September 30, 2024** | **For the Three Months Ended September 30, 2024** | **For the Three Months Ended September 30, 2024** | **For the Three Months Ended September 30, 2024** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional<br>Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated<br>Other<br>Comprehensive**<br>**(Loss) Income** | **Total<br>Stockholders'**<br>**Equity** |
| Balance at June 30, 2024 | 11498917 | $1 | $579510 | $(453580) | $(388) | $125543 |
| Issuance of common stock, net of issuance costs | 668379 |  | 35842 |  |  | 35842 |
| Issuance of common stock upon cashless exercise of warrants | 6087 |  |  |  |  |  |
| Issuance of common stock upon exercise of stock options | 2588 |  | 58 |  |  | 58 |
| Issuance of common stock upon vesting of restricted stock units | 3511 |  |  |  |  |  |
| Stock-based compensation expense |  |  | 2243 |  |  | 2243 |
| Change in unrealized gain (loss) on marketable debt securities |  |  |  |  | 595 | 595 |
| Net loss |  |  |  | (13783) |  | (13783) |
| Balance at September 30, 2024 | 12179482 | $1 | $617653 | $(467363) | $207 | $150498 |

---

See notes to the unaudited condensed consolidated financial statements.

------

**Corbus Pharmaceuticals Holdings, Inc.**

**Condensed Consolidated Statements of Stockholders' Equity**

**(in thousands, except share amounts)** 

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** | **For the Nine Months Ended September 30, 2025** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional<br>Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated<br>Other<br>Comprehensive**<br>**(Loss) Income** | **Total<br>Stockholders'**<br>**Equity** |
| Balance at December 31, 2024 | 12179482 | $1 | $619285 | $(476893) | $35 | $142428 |
| Issuance of common stock, net of issuance costs | 272938 |  | 2880 |  |  | 2880 |
| Issuance of common stock upon vesting of restricted stock units | 82433 |  |  |  |  |  |
| Stock-based compensation expense |  |  | 4859 |  |  | 4859 |
| Change in unrealized gain (loss) on marketable debt securities |  |  |  |  | (38) | (38) |
| Net loss |  |  |  | (57982) |  | (57982) |
| Balance at September 30, 2025 | 12534853 | $1 | $627024 | $(534875) | $(3) | $92147 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Nine Months Ended September 30, 2024** | **For the Nine Months Ended September 30, 2024** | **For the Nine Months Ended September 30, 2024** | **For the Nine Months Ended September 30, 2024** | **For the Nine Months Ended September 30, 2024** | **For the Nine Months Ended September 30, 2024** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional<br>Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Accumulated<br>Other<br>Comprehensive**<br>**(Loss) Income** | **Total<br> Stockholders'**<br>**Equity** |
| Balance at December 31, 2023 | 4423683 | $- | $429780 | $(436684) | $(1) | $(6905) |
| Issuance of common stock, net of issuance costs | 7462916 | 1 | 180236 |  |  | 180237 |
| Issuance of common stock upon cashless exercise of warrants | 6087 |  |  |  |  |  |
| Issuance of common stock upon conversion of K2 Loan and Security Agreement | 142857 |  | 1125 |  |  | 1125 |
| Issuance of common stock upon exercise of stock options | 136664 |  | 1999 |  |  | 1999 |
| Issuance of common stock upon vesting of restricted stock units | 7275 |  |  |  |  |  |
| Stock-based compensation expense |  |  | 4513 |  |  | 4513 |
| Change in unrealized gain (loss) on marketable debt securities |  |  |  |  | 208 | 208 |
| Net loss |  |  |  | (30679) |  | (30679) |
| Balance at September 30, 2024 | 12179482 | $1 | $617653 | $(467363) | $207 | $150498 |

---

See notes to the unaudited condensed consolidated financial statements.

------

**Corbus Pharmaceuticals Holdings, Inc.**

**Condensed Consolidated Statements of Cash Flows**

**(in thousands)** 

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
|  | **2025** | **2024** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(57982) | $(30679) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 4859 | 4513 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 184 | 454 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net amortization of premiums and discounts on investments | (674) | (2500) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount |  | 396 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (242) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in prepaid expenses and other current assets | 337 | 1129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in other assets |  | 212 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in operating lease right-of-use asset | 776 | 686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in other long-term liabilities |  | (44) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in accounts payable | (1785) | (75) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accrued expenses | 7147 | (3868) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in operating lease liabilities | (1190) | (1066) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (48570) | (30852) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of investments | (73069) | (169563) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of investments | 128573 | 39523 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 55504 | (130040) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock, net | 2851 | 182071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment of notes payable |  | (301) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment of long-term borrowings |  | (15179) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 2851 | 166591 |
| Net increase in cash, cash equivalents, and restricted cash | 9785 | 5699 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 17868 | 14394 |
| Cash, cash equivalents, and restricted cash at end of the period | $27653 | $20093 |
| Supplemental disclosure of cash flow information and non-cash transactions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest | $— | $2818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issuance costs not yet paid | $75 | $75 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock for conversion of convertible debt | $— | $1125 |

---

See notes to the unaudited condensed consolidated financial statements.

------

**Corbus Pharmaceuticals Holdings, Inc.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**September 30, 2025**

**1. NATURE OF BUSINESS AND BASIS OF PRESENTATION**

***Nature of Business***

Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a clinical-stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE") and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company's business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable, and it may never achieve profitability.

***Basis of Presentation***

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") for interim financial reporting. In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the condensed consolidated financial position of the Company as of September 30, 2025 and the results of its operations and changes in stockholders' equity for the three and nine months ended September 30, 2025 and 2024 and its cash flows for the nine months ended September 30, 2025 and 2024. Certain amounts in the prior year's financial statements have been reclassified to conform with the current year presentation. These reclassifications did not impact previously reported net loss or cash flows. The December 31, 2024 condensed consolidated balance sheet was derived from audited financial statements. The Company prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (the "SEC") for interim reporting. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 11, 2025 (the "2024 Annual Report"). The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.

***Basis of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.

The significant accounting policies used in preparation of these condensed consolidated financial statements in this Form 10-Q are consistent with those discussed in Note 3, "Significant Accounting Policies," in our 2024 Annual Report.

***Recently Adopted Accounting Pronouncements***

In November 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures*, which requires entities to disclose disaggregated information about their effective tax rate reconciliations as well as expanded information on income taxes by jurisdiction. The standard is effective for fiscal years beginning after December 15, 2024 on a prospective basis. The Company discloses its income tax rate reconciliation in its annual consolidated financial statements only and does not expect the adoption to have a material impact on its consolidated financial statements.

------

***Government Tax Credits***

The Company is eligible to receive tax credits in the form of refundable research and development tax credits and the employee retention tax credit ("ERTC"). The Company may qualify for refundable research and development tax credits from foreign authorities in the form of cash that are earned on certain research and development expenses incurred primarily outside of the United States ("U.S.") by its foreign subsidiaries in the United Kingdom ("U.K.") and Australia. Under the Coronavirus Aid, Relief, and Economic Security Act of 2020, or CARES Act, the Company was eligible to claim the ERTC, which is a refundable tax credit against certain employment taxes. The Company records these tax credits as other income, net when the Company has reasonable assurance any conditions attached to the assistance have been met and the assistance will be received. The Company recognized no income from government tax credits for the three months ended September 30, 2025 and 2024 and $1.1 million and $2.5 million in government tax credits to other income, net for the nine months ended September 30, 2025 and 2024, respectively. These amounts have been received as of September 30, 2025 and no future conditions impact the recognition of these tax credits. As of September 30, 2025, the prepaid expenses and other current assets line within the condensed consolidated balance sheet includes $1.5 million related to government tax credits that were recorded during the fourth quarter of 2024 that have not yet been received.

**2. LIQUIDITY**

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses since inception and as of September 30, 2025, had an accumulated deficit of approximately $534.9 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its pre-clinical and clinical programs, strategic alliances, and the development of its administrative organization. Based on current operating plans and assumptions regarding clinical timelines and other planned expenditures, the Company expects that its cash, cash equivalents, and investments of approximately $104.0 million at September 30, 2025, together with net proceeds of $73.8 million from the sale of common stock under the Open Market Sales Agreement and the 2025 public offering (see Note 16), will be sufficient to meet its operating and capital requirements at least twelve months from the issuance of this Quarterly Report on Form 10-Q.

The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company's clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company to, among other things, delay, scale back or eliminate some or all of the Company's planned clinical or pre-clinical trials.

**3. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH**

The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90 days from the date of purchase to be cash equivalents. At September 30, 2025 and December 31, 2024, cash equivalents were comprised of money market funds and corporate debt securities with maturities less than 90 days from the date of purchase.

Restricted cash as of September 30, 2025 included security for a stand-by letter of credit issued in favor of a landlord for $0.7 million of which $0.3 million was classified in current assets and $0.4 million was classified in noncurrent assets as of September 30, 2025.

Cash, cash equivalents, and restricted cash consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31, 2024** |
| Cash | $1498 | $5047 |
| Cash equivalents | 25485 | 12151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 26983 | 17198 |
| Restricted cash, current | 285 | 285 |
| Restricted cash, noncurrent | 385 | 385 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 670 | 670 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash<br> flows | $27653 | $17868 |

---

------

As of September 30, 2025, the Company's cash and cash equivalents held in the U.S. was approximately $25.8 million and approximately $1.2 million of cash was held in its subsidiaries in the U.K. and Australia. As of December 31, 2024, all of the Company's cash was held in the U.S., except for approximately $4.9 million of cash which was held in its subsidiaries in the U.K. and Australia.

**4. INVESTMENTS**

The following table summarizes the Company's investments as of September 30, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Amortized Cost** | **Gross<br>Unrealized<br>Gain** | **Gross<br>Unrealized<br>Losses** | **Fair Value** |
| **Debt Securities:** |  |  |  |  |
| &nbsp;&nbsp;U.S. Treasury securities | $6057 | $4 | $- | $6061 |
| &nbsp;&nbsp;U.S. government agency securities | 7436 | 2 | - | 7438 |
| &nbsp;&nbsp;Commercial paper | 2490 | - | - | 2490 |
| &nbsp;&nbsp;Corporate debt securities | 61016 | 18 | (24) | 61010 |
| **Total** | $76999 | $24 | $(24) | $76999 |

---

The following table summarizes the amortized cost and fair value of the Company's available-for-sale marketable debt securities by contractual maturity as of September 30, 2025 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Amortized Cost** | **Fair Value** |
| Maturing in one year or less | $69376 | $69375 |
| Maturing after one year but less than three years | 7623 | 7624 |
|  | $76999 | $76999 |

---

The following table summarizes the Company's investments as of December 31, 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Amortized Cost** | **Gross<br>Unrealized<br>Gain** | **Gross<br>Unrealized<br>Losses** | **Fair Value** |
| **Debt Securities:** |  |  |  |  |
| &nbsp;&nbsp;U.S. Treasury securities | $9452 | $15 | $- | $9467 |
| &nbsp;&nbsp;U.S. government agency securities | 22075 | 18 | - | 22093 |
| &nbsp;&nbsp;Corporate debt securities | 100302 | 56 | (54) | 100304 |
| **Total** | $131829 | $89 | $(54) | $131864 |

---

The following table summarizes the amortized cost and fair value of the Company's available-for-sale marketable debt securities by contractual maturity as of December 31, 2024 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Amortized Cost** | **Fair Value** |
| Maturing in one year or less | $126870 | $126930 |
| Maturing after one year but less than three years | 4959 | 4934 |
|  | $131829 | $131864 |

---

**5. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES**

The following table presents information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2025 (in thousands):

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $19215 | $— | $— | $19215 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities |  | 6270 |  | 6270 |
| Investments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Treasury securities |  | 6061 |  | 6061 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government agency securities |  | 7438 |  | 7438 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 2490 |  | 2490 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities |  | 61010 |  | 61010 |
|  | $19215 | $83269 | $— | $102484 |

---

The following table presents information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $12151 | $— | $— | $12151 |
| Investments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Treasury securities |  | 9467 |  | 9467 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government agency securities |  | 22093 |  | 22093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities |  | 100304 |  | 100304 |
|  | $12151 | $131864 | $— | $144015 |

---

**6. LICENSE AGREEMENTS**

The Company entered into a license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), a privately held Delaware limited liability company, effective September 20, 2018. Pursuant to the Jenrin License Agreement, Jenrin granted the Company exclusive worldwide rights to develop and commercialize the Licensed Products (as defined in the Jenrin License Agreement) which includes the Jenrin library of over 600 compounds and multiple issued and pending patent filings. The compounds are designed to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.

In consideration of the license and other rights granted by Jenrin, the Company paid Jenrin a $0.3 million upfront cash payment and is obligated to pay Jenrin up to $18.4 million in potential milestone payments for each compound it elects to develop based upon the achievement of specified development and regulatory milestones. In addition, the Company is obligated to pay Jenrin royalties in the mid, single digits based on net sales of any Licensed Products, subject to specified reductions. The Company achieved the first milestone in the amount of $0.4 million associated with the progression into a clinical trial for CRB-913 during the first quarter of 2025, which was subsequently paid in the second quarter of 2025. The Company is obligated to pay Jenrin up to $18.0 million in additional potential milestone payments for further development of CRB-913.

The Company entered into a license agreement (the "UCSF License Agreement") with the Regents of the University of California ("The Regents") effective May 26, 2021. Pursuant to the UCSF License Agreement, the Company received an exclusive license to certain patents relating to humanized antibodies against integrin αvβ8, one of which the Company is referring to as CRB-601, along with non-exclusive licenses to certain related know-how and materials. The Company amended the UCSF License Agreement with The Regents effective November 17, 2022, adding additional antibody patents to the agreement.

In consideration for the license and other rights granted to the Company under the UCSF License Agreement, the Company paid The Regents a license issue fee of $1.5 million. In consideration for the additional antibody patents granted to the Company, the Company paid The Regents a license issue fee of $0.8 million, paid in two equal installments of $0.4 million.

The Company further amended the UCSF License Agreement with The Regents effective August 14, 2023 to incorporate certain new technology rights and amend the payment schedule for the development milestone for the filing of patent rights and the development milestone for the filing of an Investigational New Drug ("IND").

------

In addition to the license issuance fees, the Company is obligated to pay an annual license maintenance fee, as well as up to $150.8 million in remaining potential milestone payments, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50.0 thousand for each new indication, for the achievement of certain development, regulatory, and sales milestones. In addition, the Company is also obligated to pay royalties in the lower, single digits on sales of products falling within the scope of the licensed patents, which is subject to a minimum annual royalty obligation, and a percentage share of certain payments received by the Company from sublicensees or in connection with the sale of the licensed program. During the first quarter of 2025, the Company paid $1.6 million under the UCSF License Agreement for previously achieved milestone payments. This amount was included within accounts payable within the condensed consolidated balance sheet as of December 31, 2024.

The Company entered into a license agreement (the "CSPC License Agreement") with CSPC Megalith Biopharmaceutical Co., Ltd. ("CSPC"), a subsidiary of CSPC Pharmaceutical Group Limited, effective February 12, 2023. Pursuant to the CSPC License Agreement, the Company received an exclusive license to develop and commercialize a novel clinical stage ADC targeting Nectin-4, which the Company is referring to as CRB-701, in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Australia.

In consideration for the license granted to the Company under the CSPC License Agreement, the Company paid CSPC an upfront payment of $7.5 million ($5.0 million paid at signing during the first quarter of 2023 followed by $2.5 million paid during the third quarter of 2024). The Company is obligated to pay potential milestone payments to CSPC totaling up to $130.0 million based upon the achievement of specified development and regulatory milestones and $555.0 million in potential commercial milestone payments. In addition, we are obligated to pay royalties in the low double digits based on net sales of any Licensed Products, as defined in the CSPC License Agreement.

The Company determined that substantially all of the fair value of the Jenrin License Agreement, UCSF License Agreement and CSPC License Agreement was attributable to a single or separate groups of in-process research and development assets which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process research and development assets. Thus, the Company recorded the various upfront payments to research and development expenses in the quarter the license deals became effective. The Company will account for the development, regulatory, and sales milestone payments in the period that the relevant milestones are achieved as either research and development expense or as an intangible asset as applicable. Research and development expenses associated with upfront payments and clinical milestones was $0 and $0.4 million for the three and nine months ended September 30, 2025, respectively, related to the CRB-913 milestone payment in accordance with the Jenrin License Agreement. For the three and nine months ended September 30, 2024, no research and development expense associated with upfront payments or clinical milestones were incurred under any of the above agreements.

**7** **. PROPERTY AND EQUIPMENT**

Property and equipment consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,<br>2025** | **December 31,<br>2024** |
| Computer hardware and software | $13 | $13 |
| Office furniture and equipment | 1114 | 1114 |
| Leasehold improvements | 3331 | 3331 |
| Property and equipment, gross | 4458 | 4458 |
| Less: accumulated depreciation | (4257) | (4073) |
| Property and equipment, net | $201 | $385 |

---

Depreciation expense was $0.1 million and $0.2 million for the three months ended September 30, 2025 and 2024, respectively and $0.2 million and $0.5 million for the nine months ended September 30, 2025 and 2024, respectively.

The Company notes no impairment charges were taken during the three and nine months ended September 30, 2025 and 2024.

------

**8** **. COMMITMENTS AND CONTINGENCIES**

**Operating Lease Commitment**

Pursuant to the terms of the Company's non-cancelable lease agreements in effect at September 30, 2025, the following table summarizes the Company's maturities of operating lease liabilities as of September 30, 2025 (in thousands):

---

| | |
|:---|:---|
| 2025 | $451 |
| 2026 | 1688 |
| Total lease payments | 2139 |
| Less: imputed interest | (90) |
| Total | $2049 |

---

**Sublease Commitment**

Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and was scheduled to end on October 31, 2026, however, it was terminated on June 24, 2024. The Company recorded no sublease income for the three and nine months ended September 30, 2025 and sublease expense of $0 and $0.2 million for the three and nine months ended September 30, 2024.

**9. NOTES PAYABLE**

***Loan and Security Agreement with K2 HealthVentures LLC***

On July 28, 2020, the Company, with its subsidiary, Corbus Pharmaceuticals, Inc., as borrower, entered into a secured Loan and Security Agreement with K2 HealthVentures LLC ("K2HV"), an unrelated third party (the "Loan and Security Agreement") and received $20.0 million upon signing. On August 1, 2024, the loan matured and the Company made a final payment in the amount of $11.8 million, which represented $10.1 million principal outstanding on the maturity date, $1.6 million final payment and accrued interest. The $1.6 million final payment was amortized over the life of the loan through interest expense within the condensed consolidated statements of operations and comprehensive loss. Interest payments were made monthly and accrued at a variable annual rate equal to the greater of (i) 8.5% and (ii) the rate of interest noted in The Wall Street Journal, Money Rates section, as the "Prime Rate" plus 5.25%.

The Company entered into an Amendment to the Loan and Security Agreement (the "Amended Loan and Security Agreement") on October 25, 2022. Pursuant to the Amended Loan and Security Agreement, K2HV could elect to convert up to $5.0 million of the outstanding loan balance into shares of the Company's common stock at conversion prices as follows: $0.9 million of the loan at $4.50 per share, $1.1 million at $7.875 per share, and $3.0 million at $282.00 per share. On June 1, 2023, K2HV converted $0.9 million of the outstanding loan balance into 194,444 shares of the Company's stock at a conversion price of $4.50 per share. On March 6, 2024, K2HV converted $1.1 million of the outstanding loan balance into 142,857 shares of the Company's stock at a conversion price of $7.875 per share.

In connection with the Loan and Security Agreement, on July 28, 2020, the Company issued K2HV a warrant to purchase up to 2,873 common shares (the "K2 Warrant") at an exercise price of $208.80. The K2 Warrant may be exercised either for cash or on a cashless "net exercise" basis and expires on July 28, 2030.

The total debt discount related to the Amended Loan and Security Agreement of approximately $3.0 million was charged to interest expense using the effective interest method over the term of the debt. Interest expense for the three and nine months ended September 30, 2024 was approximately $0.4 million and $1.8 million, respectively.

------

**10. ACCRUED EXPENSES**

Accrued expenses consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,<br>2025** | **December 31,<br>2024** |
| Accrued pre-clinical and clinical costs | $8859 | $2424 |
| Accrued product development costs | 961 | 280 |
| Accrued compensation | 2414 | 2276 |
| Accrued administrative costs | 344 | 446 |
| Total | $12578 | $5426 |

---

**11. NET LOSS PER COMMON SHARE**

Basic and diluted net loss per share of the Company's common stock has been computed by dividing net loss by the weighted average number of shares outstanding during the period. For years in which there is a net loss, options, warrants and RSUs are anti-dilutive and therefore excluded from diluted loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2025 and 2024 (in thousands except share and per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net loss | $(23342) | $(13783) | $(57982) | $(30679) |
| Weighted average number of common shares-basic and diluted | 12307298 | 12014700 | 12250315 | 10490981 |
| Net loss per share of common stock-basic and diluted | $(1.90) | $(1.15) | $(4.73) | $(2.92) |

---

The following common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **September 30,** |
|  | **2025** | **2024** |
| Stock options | 1,436,569 | 744,332 |
| Unvested restricted stock units | 496,405 | 254,238 |
| Warrants | 2,873 | 36,207 |

---

**12. STOCKHOLDERS' EQUITY**

***Preferred Stock***

The Company has authorized 10,000,000 shares of preferred stock, $0.0001 par value per share, of which 0 shares were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

***Common Stock***

The Company has authorized 300,000,000 shares of common stock, $0.0001 par value per share, of which 12,534,853 and 12,179,482 shares were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

***2024 Public Offering***

On January 31, 2024, the Company entered into an underwriting agreement with Jefferies LLC ("Jefferies"), as representative of the several underwriters, relating to an underwritten public offering of 4,325,000 shares of the Company's common stock, par value $0.0001, at a price to the public of $19.00 per share. The underwriters were also granted a 30-day option to purchase up to an additional 648,750 shares of common stock at the public offering price. On January 31, 2024, Jefferies gave notice to the Company of the underwriters' election to exercise the option to purchase additional shares, in full. On February 2, 2024, the Company completed the public offering raising gross proceeds of approximately $94.5 million and net proceeds of $88.6 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

------

***Open Market Sale Agreement***

On May 31, 2023, the Company entered into Amendment No. 1 to the Open Market Sale Agreement originally dated August 6, 2020 (as amended, the "Open Market Sale Agreement") with Jefferies, as sales agent. Under the Open Market Sale Agreement, the Company may issue and sell, from time to time through Jefferies, shares of its common stock having an aggregate offering price of up to $150.0 million (the "2024 Open Market Offering").

Under the Open Market Sale Agreement, Jefferies may sell the common stock by any method permitted by law deemed to be an "at-the-market offering" as defined by Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell common stock in amounts and at times to be determined by the Company subject to the terms and conditions of the Open Market Sale Agreement, but the Company has no obligation to sell any of the common stock in the 2024 Open Market Offering.

The Company has agreed to pay Jefferies a commission of 3.0% of the aggregate gross proceeds from each sale of common stock and have agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses.

During the three and nine months ended September 30, 2025, the Company sold 272,938 shares of its common stock, under the Open Market Sale Agreement, for net proceeds of approximately $2.9 million. As of September 30, 2025, approximately $73.4 million was available for issuance and sale under the 2024 Open Market Offering.

During the three and nine months ended September 30, 2024, the Company sold 663,730 and 2,484,517 shares of its common stock, respectively, under the Open Market Sale Agreement, for net proceeds of approximately $35.6 million and $91.4 million, respectively.

***Other Common Stock Transactions***

During the three and nine months ended September 30, 2025, the Company issued 7,846 and 82,433 common shares from the vesting of shares from restricted stock units ("RSUs"), respectively, of which 7,533 and 28,540, respectively, were issued under the 2024 Equity Compensation Plan (the "2024 Plan") and the remaining were issued under the 2014 Equity Incentive Plan (the "2014 Plan"). During the three and nine months ended September 30, 2024, the Company issued 3,511 and 7,275 common shares from the vesting of shares from RSUs, respectively, of which 2,783 were issued under the 2024 Plan and the remaining were issued under the 2014 Plan.

During the three and nine months ended September 30, 2024, the Company issued 2,588 and 136,664 shares of common stock upon the exercise of stock options to purchase common stock, and the Company received proceeds of $0.1 million and $2.0 million from those exercises, respectively. No exercises of stock options occurred during the three and nine months ended September 30, 2025.

During the three and nine months ended September 30, 2024, the Company issued 0 and 142,857 shares of common stock in a conversion pursuant to the K2HV Amended Loan and Security Agreement, respectively. No such amounts were issued during the three and nine months ended September 30, 2025.

During the three and nine months ended September 30, 2024, the Company issued 4,649 shares of common stock pursuant to a professional services agreement with an investor relations service provider. No shares of common stock were issued pursuant to a professional services agreement during the three and nine months ended September 30, 2025.

During the three and nine months ended September 30, 2024, the Company issued 6,087 shares of common stock upon the exercise of warrants. No warrants were exercised during the three and nine months ended September 30, 2025.

**13. STOCK-BASED COMPENSATION AWARDS**

On May 16, 2024, the Company's stockholders approved the 2024 Plan authorizing the issuance of up to 2,000,000 shares, succeeding the 2014 Plan, under which no further grants may be made pursuant to the terms of the 2014 Plan. Pursuant to the 2024 Plan, the Board may grant nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, RSUs, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, non-employee directors, and other individual service providers.

------

Under the terms of the 2024 Plan and 2014 Plan, the Company granted stock options and RSUs to employees, officers, non-employee directors, consultants and advisors. Stock options have a ten-year term and an exercise price equal to the fair market value of a share of our common stock on the grant date. Stock options generally vest over four years with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, except for grants to non-employee directors that vest annually. RSUs generally vest over a period of one to four years in annual installments beginning on the first anniversary of the grant date.

As of September 30, 2025, an aggregate of 826,853 shares of common stock were reserved for issuance upon the exercise or vesting of outstanding awards under the 2014 Plan. No additional grants can be made under the 2014 Plan.

As of September 30, 2025, an aggregate of 1,106,121 shares of common stock were reserved for issuance upon the exercise or vesting of outstanding awards and up to 862,556 shares of common stock may be issued pursuant to awards granted under the 2024 Plan.

***Stock-based Compensation Expense***

In connection with all stock-based compensation awards, total non-cash, stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Research and development expenses | $509 | $305 | $1451 | $709 |
| General and administrative expenses | 1073 | 1938 | 3408 | 3804 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $1582 | $2243 | $4859 | $4513 |

---

The total stock-based compensation expense recognized by award type was as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Stock options | $948 | $1509 | $2853 | $3231 |
| Restricted stock units | 634 | 734 | 2006 | 1282 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $1582 | $2243 | $4859 | $4513 |

---

*<u>Stock Options</u>*

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes stock option pricing model that uses the assumptions noted in the following table, except for the expected term for non-employees as noted in the following paragraph. The expected term of employee and non-employee director stock options granted under the 2014 Plan and 2024 Plan, all of which qualify as "plain vanilla" per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company's limited operating history. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among our employee population. For non-employee stock options, excluding directors, the Company has elected to utilize the contractual term as the expected term. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with that used to value the stock option. The Company accounts for forfeitures as they occur.

The weighted average assumptions used principally in determining the fair value of stock options granted to employees and non-employee directors were as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| Risk-free interest rate | 4.35% | 4.23% |
| Expected dividend yield | 0% | 0% |
| Expected term in years | 6.15 | 6.17 |
| Expected volatility | 131.47% | 124.46% |

---

------

A summary of stock option activity for the nine months ended September 30, 2025 is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Stock Options** | **Shares** | **Weighted<br> Average<br>Exercise<br> Price** | **Weighted Average<br> Remaining Contractual Term in Years** | **Aggregate<br>Intrinsic <br>Value (in thousands)** |
| Outstanding at December 31, 2024 | 723153 | $62.95 | 6.95 | $881 |
| Granted | 716250 | 9.31 |  |  |
| Exercised |  |  |  |  |
| Forfeited or canceled |  |  |  |  |
| Expired | (2834) | 47.83 |  |  |
| Outstanding at September 30, 2025 | 1436569 | $36.24 | 7.74 | $3410 |
| Exercisable at September 30, 2025 | 530712 | $78.21 | 5.39 | $658 |

---

The weighted average grant-date fair value of stock options granted during the nine months ended September 30, 2025 and 2024 was $8.47 and $25.17 per share, respectively. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2025 and 2024 was $0 and $1.1 million, respectively. As of September 30, 2025, there was $8.3 million of total unrecognized compensation expense related to unvested stock-based option compensation arrangements, which are expected to be recognized over a weighted average period of 1.46 years.

*<u>Restricted Stock Units</u>*

A RSU represents the right to receive one share of our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of our common stock on the date of grant. The Company accounts for forfeitures as they occur.

A summary of RSU activity for the nine months ended September 30, 2025 is presented below:

---

| | | |
|:---|:---|:---|
| **RSUs** | **Number of Shares Underlying RSUs** | **Weighted<br> Average<br>Grant Date Fair Value** |
| Unvested at December 31, 2024 | 259488 | $26.42 |
| Granted | 319350 | $9.20 |
| Forfeited |  | $— |
| Vested | (82433) | $29.83 |
| Unvested at September 30, 2025 | 496405 | $14.78 |

---

As of September 30, 2025, there was $6.0 million of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average period of 1.82 years.

**14. WARRANTS**

No warrants were exercised during the three and nine months ended September 30, 2025. During the three and nine months ended September 30, 2024, the Company issued 6,087 shares of common stock upon the exercise of warrants.

At September 30, 2025, there were warrants outstanding to purchase 2,873 shares of common stock with a weighted average exercise price of $208.80 and a weighted average remaining life of 4.83 years.

On January 26, 2018, the Company entered into an Investment Agreement with the Cystic Fibrosis Foundation ("CFF") that included issuance of a warrant to purchase an aggregate of 33,334 shares of the Company's common stock (the "CFF Warrant") at an exercise price of $396.00 per share. The CFF Warrant expired unexercised on January 26, 2025.

On July 28, 2020, the Company entered into the Loan and Security Agreement with K2HV and in connection with the funding of $20.0 million, the Company issued a warrant exercisable for 2,873 shares of the Company's common stock (the "K2 Warrant") at an exercise price of $208.80 per share. The K2 Warrant is immediately exercisable for 2,873 shares and expires on July 28, 2030.

------

**15. SEGMENT INFORMATION**

The Company views its operations and manages its business in one reportable segment, which is developing and commercializing therapeutics for cancer and obesity.

The Company's Chief Executive Officer is the Chief Operating Decision Maker ("CODM"). The CODM makes decisions based on net income (loss). Significant expenses within net income (loss) include research and development and general and administrative expenses, which are each separately presented on the Company's condensed consolidated statements of operations and comprehensive loss. Other segment items within net income (loss) include interest and investment income, net, interest expense and other income, net.

The measure of segment assets is reported on the condensed consolidated balance sheets as total consolidated assets. All material long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.

**16. SUBSEQUENT EVENTS**

***Open Market Sale Agreement***

From October 1, 2025 through the date of filing, the Company has sold 232,279 shares of its common stock pursuant to the Open Market Sale Agreement for which the Company received net proceeds of approximately $3.6 million.

***2025 Public Offering***

On October 30, 2025, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters, relating to an underwritten public offering of 4,744,231 shares of common stock at a price to the public of $13.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,025,000 shares of common stock at a public offering price of $12.9999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. The underwriters were also granted a 30-day option to purchase up to an additional 865,384 shares of common stock at the public offering price. On November 3, 2025, the Company completed the public offering raising gross proceeds of approximately $75.0 million and net proceeds of approximately $70.2 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

------

---

| | |
|:---|:---|
| **Item 2.** | **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.** |

---

*The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under "Risk Factors."*

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential" and other similar words and expressions of the future.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our history of operating losses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our current and future capital requirements and our ability to satisfy our capital needs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to complete required clinical trials of our product and obtain approval from the FDA or other regulatory agents in different jurisdictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to internally develop new product candidates, intellectual property, and other product candidates we may acquire and/or license;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain or protect the validity of our patents and other intellectual property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to retain key executive members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•interpretations of current laws and the passages of future laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•acceptance of our business model by investors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the accuracy of our estimates regarding expenses and capital requirements; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to adequately support growth.

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see "Risk Factors" for additional risks which could adversely impact our business and financial performance.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs, or projections will result or be achieved or accomplished.

------

**Overview**

Corbus Pharmaceuticals Holdings, Inc. (the "Company," "Corbus," "we," "us," or "our") is a clinical-stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Our pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE"); and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity.

**Our oncology pipeline:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•CRB-701 is a next-generation ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of MMAE. In February 2023, we obtained a license from CSPC Megalith Biopharmaceutical Co. Ltd. ("CSPC"), a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States ("U.S."), Canada, the European Union (including the European Free Trade Area), the United Kingdom ("U.K.") and Australia. CRB-701 (SYS6002) is currently being investigated by CSPC in a Phase 1/2 clinical trial in participants with advanced solid tumors in China (the "China study"). We commenced a corresponding Phase 1/2 study in the U.S. and the U.K. (the "Western study") in April 2024 and completed enrollment of the dose escalation phase in October 2024. Both studies are enrolling participants with advanced solid tumors associated with Nectin-4 expression. Subsequent to the completion of enrollment in the dose escalation phase, we began enrolling the dose optimization portion of the Western study, added additional clinical sites in Europe, and in June 2025 began dosing participants in the PD-1 combination arm with CRB-701 in combination with Keytruda® (pembrolizumab). We presented the dose optimization data at the European Society for Medical Oncology ("ESMO") in October 2025. Data as of September 1, 2025 was presented from 167 patients, of whom 122 were evaluable for efficacy, from the U.S. and Europe with head and neck squamous cell carcinoma ("HNSCC"), cervical, locally advanced/metastatic urothelial ("mUC") tumors and other solid-tumor types. We expect to engage and consult with the FDA regarding the design of a registrational study and anticipate commencing this study by mid-2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•CRB-601 is a potent and selective anti-αvβ8 monoclonal antibody that blocks the activation of latent TGFβ found on cancer cells. In pre-clinical models, CRB-601 demonstrates enhanced anti-tumor activity when combined with an anti-PD-1 checkpoint inhibitor compared to each single agent on its own. Pre-clinical data suggests that blockade of latent TGFβ production by CRB-601 can lead to changes in immune cell infiltration in the tumor microenvironment, thus potentially enhancing the benefit of PD-1 blockade. CRB-601 is being developed as a potential treatment for participants with solid tumors in combination with existing therapies, including checkpoint inhibitors. The first participant in a Phase 1 dose escalation study was dosed in December 2024 under an open IND and regulatory approval for the study was received in the U.K. in January 2025. Dose escalation in combination with Keytruda® (pembrolizumab) commenced in June 2025. In November 2025, we presented a study-in-progress poster at the 2025 Society for Immunotherapy of Cancer ("SITC") conference and dose escalation is on-going.

**Our obesity pipeline:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•CRB-913 is a second-generation highly peripherally restricted CB1 receptor inverse agonist designed to treat obesity. We dosed the first participant in the single ascending dose ("SAD") portion of a Phase 1 study in the first quarter of 2025 and thus far have observed an absence of treatment-related neuropsychiatric events. In June 2025, we dosed the first participant in the multiple ascending dose ("MAD") portion of the Phase 1 trial. We expect to report SAD/MAD data, as well as initiate a Phase 1b dose-range finding study in obese non-diabetic individuals in the fourth quarter of 2025. CB1 inverse agonism is a clinically validated mechanism known to induce weight loss; however, neuropsychiatric adverse events have been reported in prior clinical studies with both rimonabant and monlunabant. CRB-913 has been specifically formulated to shift the drug exposure from the brain to the periphery to improve safety and tolerability. The drug was shown in pre-clinical studies to have a brain-to-plasma ratio fifty times lower than rimonabant and fifteen times more peripherally restricted than monlunabant.

------

**Recent Developments**

***Open Market Sale Agreement***

On May 31, 2023, the Company entered into Amendment No. 1 to the Open Market Sale Agreement originally dated August 6, 2020 (as amended, the "Open Market Sale Agreement") with Jefferies LLC ("Jefferies"), as sales agent. Under the Open Market Sale Agreement, we may issue and sell, from time to time through Jefferies, shares of its common stock having an aggregate offering price of up to $150.0 million. During the three and nine months ended September 30, 2025, we sold an aggregate of 272,938 shares of common stock, under the Open Market Sale Agreement, for net proceeds of approximately $2.9 million. From October 1, 2025 through the date of filing, the Company has sold approximately 232,279 shares of its common stock pursuant to the Open Market Sale Agreement for which the Company received net proceeds of approximately $3.6 million.

***2025 Public Offering***

On October 30, 2025, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters, relating to an underwritten public offering of 4,744,231 shares of the Company's common stock, par value $0.0001, at a price to the public of $13.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,025,000 shares of common stock at a public offering price of $12.9999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. The underwriters were also granted a 30-day option to purchase up to an additional 865,384 shares of common stock at the public offering price. On November 3, 2025, the Company completed the public offering raising gross proceeds of approximately $75.0 million and net proceeds of approximately $70.2 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

**Financial Operations Overview**

We are an oncology and obesity company and have not generated any revenues from the sale of products. We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for the marketing of one of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. We have never been profitable and at September 30, 2025, we had an accumulated deficit of approximately $534.9 million. Our net losses for the three months ended September 30, 2025 and 2024, were approximately $23.3 million and $13.8 million, respectively. Our net losses for the nine months ended September 30, 2025 and 2024, were approximately $58.0 million and $30.7 million, respectively.

We expect to continue to incur significant expenses for the foreseeable future. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of our product candidates. We will continue to incur significant operating losses as we move into the clinical phase and, accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity, debt financings or other sources, which may include government grants and collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

We expect to continue to incur operating losses for at least the next several years in connection with our ongoing activities, as we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•conduct pre-clinical and clinical trials for our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•continue our research and development efforts; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•manufacture and purchase drugs for clinical studies.

**Critical Accounting Policies and Estimates**

Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenue, costs of expenses and related disclosures in the condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on historical experience, current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

------

There have been no changes to the critical accounting estimates we identified in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 11, 2025 (the "2024 Annual Report").

**Results of Operations**

***Comparison of Three Months Ended September 30, 2025 and 2024***

**Operating Expense.** The following table summarizes our operating expenses for the three months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Research and development expense | $20860 | $10808 | $10052 | 93% |
| General and administrative expense | 3557 | 4697 | (1140) | -24% |
| &nbsp;&nbsp;Total operating expenses | $24417 | $15505 | $8912 | 57% |

---

**Research and Development.** The following table summarizes our research and development expenses for the three months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Program specific costs: |  |  |  |  |
| &nbsp;&nbsp;CRB-601 | $4805 | $1248 | $3557 | 285% |
| &nbsp;&nbsp;CRB-701 | 9579 | 4202 | 5377 | 128% |
| &nbsp;&nbsp;CRB-913 | 3666 | 3225 | 441 | 14% |
| &nbsp;&nbsp;Other drug development | 128 | 132 | (4) | -3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total program specific costs | 18178 | 8807 | 9371 | 106% |
| Unallocated internal costs: |  |  |  |  |
| &nbsp;&nbsp;Personnel related | 2313 | 1528 | 785 | 51% |
| &nbsp;&nbsp;Other unallocated | 369 | 473 | (104) | -22% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total research and development expenses | $20860 | $10808 | $10052 | 93% |

---

Research and development expenses for the three months ended September 30, 2025 totaled approximately $20.9 million, an increase of $10.1 million from approximately $10.8 million recorded for the three months ended September 30, 2024.

Total program-specific costs increased by $9.4 million for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. Costs related to CRB-601 increased by $3.6 million as a result of higher clinical and drug supply related costs as the first participant in a Phase 1 dose escalation study was dosed in December 2024 and dose escalation is on-going. Costs related to CRB-701 increased by $5.4 million as a result of higher clinical costs as more sites were activated and participants enrolled in the ongoing Phase 1/2 clinical trial, which began in April 2024. CRB-913 costs increased by $0.4 million primarily due to enrollment in the SAD/MAD dose portion of the Phase 1 clinical study, which began in March 2025, partially offset by a decrease in manufacturing costs.

Personnel-related costs increased by $0.8 million for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The increase is primarily due to an increase in headcount.

We have a subsidiary in each of the U.K. and Australia. During the three months ended September 30, 2025 and 2024, approximately 40% and 41% of research and development expenses, respectively, were recorded in these entities.

**General and Administrative.** General and administrative expense for the three months ended September 30, 2025 totaled approximately $3.6 million, a decrease of $1.1 million from approximately $4.7 million recorded for the three months ended September 30, 2024. The decrease in fiscal quarter 2025 as compared to fiscal quarter 2024 was attributable to a decrease in compensation costs of $0.7 million primarily due to a decrease in stock-based compensation costs and a $0.3 million decrease in investor relations expense primarily due to issuing stock pursuant to a professional services agreement with a service provider in the prior year.

------

**Other Income, Net.** The following table summarizes our total other income, net for the three months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Interest and investment income, net | $1125 | $1903 | $(778) | -41% |
| Interest expense |  | (381) | 381 | -100% |
| Other (expense) income, net | (50) | 200 | (250) | -125% |
| &nbsp;&nbsp;Total other income, net | $1075 | $1722 | $(647) | -38% |

---

Total other income, net for the three months ended September 30, 2025 totaled approximately $1.1 million, a decrease of $0.6 million from approximately $1.7 million recorded for the three months ended September 30, 2024. The decrease in 2025 as compared to 2024 was primarily attributable to lower investment income due to lower cash and investment balances, partially offset by no interest expense on debt in 2025 as principal payments were made in 2024 ultimately leading to the final payment in August 2024.

***Comparison of Nine Months Ended September 30, 2025 and 2024***

**Operating Expense.** The following table summarizes our operating expenses for the nine months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Research and development expense | $51689 | $23435 | $28254 | 121% |
| General and administrative expense | 11655 | 12681 | (1026) | -8% |
| &nbsp;&nbsp;Total operating expenses | $63344 | $36116 | $27228 | 75% |

---

**Research and Development.** The following table summarizes our research and development expenses for the nine months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Program specific costs: |  |  |  |  |
| &nbsp;&nbsp;CRB-601 | $11431 | $3501 | $7930 | 227% |
| &nbsp;&nbsp;CRB-701 | 21885 | 9378 | 12507 | 133% |
| &nbsp;&nbsp;CRB-913 | 10207 | 5117 | 5090 | 99% |
| &nbsp;&nbsp;Other drug development | 374 | 166 | 208 | 125% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total program specific costs | 43897 | 18162 | 25735 | 142% |
| Unallocated internal costs: |  |  |  |  |
| &nbsp;&nbsp;Personnel related | 6571 | 3822 | 2749 | 72% |
| &nbsp;&nbsp;Other unallocated | 1221 | 1451 | (230) | -16% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total research and development expenses | $51689 | $23435 | $28254 | 121% |

---

Research and development expenses for the nine months ended September 30, 2025 totaled approximately $51.7 million, an increase of $28.3 million from approximately $23.4 million recorded for the nine months ended September 30, 2024.

Total program-specific costs increased by $25.7 million for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024. Costs related to CRB-601 increased by $7.9 million as a result of higher clinical and drug supply related costs as the first participant in the on-going Phase 1 dose escalation study was dosed in December 2024, partially offset by a decrease in sponsored research agreement expense. Costs related to CRB-701 increased by $12.5 million as a result of higher clinical and drug supply related costs as the Phase 1/2 clinical trial enrollment began in April 2024 and is on-going. CRB-913 costs increased by $5.1 million due to enrollment in the SAD/MAD dose portion of the Phase 1 clinical study, which began in March 2025, as well as manufacturing of drug supply for the Phase 1b dose-range finding study, which is expected to commence in the fourth quarter of 2025.

------

Personnel-related costs increased by $2.7 million for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024. The increase is primarily due to an increase in headcount.

We have a subsidiary in each of the U.K. and Australia. During the nine months ended September 30, 2025 and 2024, approximately 37% and 37% of research and development expenses, respectively, were recorded in these entities.

**General and Administrative.** General and administrative expense for the nine months ended September 30, 2025 totaled approximately $11.7 million, a decrease of $1.0 million from approximately $12.7 million recorded for the nine months ended September 30, 2024. The decrease is primarily related to a decrease in legal expenses of $0.6 million and a decrease in facility expense of $0.3 million.

**Other Income, Net.** The following table summarizes our total other income, net for the nine months ended September 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | | |
|  | **2025** | **2024** | <br>**$ Change** | <br>**% Change** |
| Interest and investment income, net | $4120 | $4531 | $(411) | -9% |
| Interest expense |  | (1872) | 1872 | -100% |
| Other income, net | 1242 | 2778 | (1536) | -55% |
| &nbsp;&nbsp;Total other income, net | $5362 | $5437 | $(75) | -1% |

---

Total other income, net was comparable for the nine months ended September 30, 2025 and 2024. Other income, net includes $1.1 million in employee retention tax credits for the nine months ended September 30, 2025 and refundable research and development credits from a foreign tax authority of $2.5 million for the nine months ended September 30, 2024. This decrease is partially offset by no interest expense on debt in 2025 as principal payments were made in 2024 leading to the final payment in August 2024.

**Liquidity and Capital Resources**

Since inception, we have experienced negative cash flows from operations. We have financed our operations primarily through sales of equity-related securities. At September 30, 2025, our accumulated deficit since inception was approximately $534.9 million.

At September 30, 2025, we had total current assets of approximately $107.6 million and current liabilities of approximately $17.1 million, resulting in working capital of approximately $90.5 million. Of our total cash, cash equivalents, investments, and restricted cash of $104.7 million at September 30, 2025, approximately $103.5 million was held within the U.S.

*Cash Flows*

The following table summarizes our cash flows for the nine months ended September 30, 2025 and 2024 (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| Net cash used in operating activities | $(48570) | $(30852) |
| Net cash provided by (used in) investing activities | 55504 | (130040) |
| Net cash provided by financing activities | 2851 | 166591 |
| &nbsp;&nbsp;Net increase in cash, cash equivalents, and restricted cash | $9785 | $5699 |

---

Net cash used in operating activities for the nine months ended September 30, 2025 was approximately $48.6 million, which includes a net loss of approximately $58.0 million, adjusted for non-cash expenses of approximately $4.1 million primarily related to stock-based compensation expense, and approximately $5.3 million of cash provided by net working capital items principally due to an increase in accrued expenses, partially offset by decreases in accounts payable and operating lease liabilities.

Cash provided by investing activities for the nine months ended September 30, 2025 totaled approximately $55.5 million, which was principally related to proceeds from sales and maturities of marketable securities.

Cash provided by financing activities for the nine months ended September 30, 2025 totaled approximately $2.9 million, which was related to the issuance of common stock. For the nine months ended September 30, 2025, we sold an aggregate of 272,938 shares of common stock under the Open Market Sale Agreement for net proceeds of approximately $2.9 million.

------

*Future Funding Requirements*

Based on current operating plans and assumptions regarding clinical timelines and other planned expenditures, we expect our cash, cash equivalents, and investments of approximately $104.0 million at September 30, 2025, together with net proceeds of $73.8 million raised from the sale of our common stock under the Open Market Sales Agreement and the 2025 Public Offering, will be sufficient to meet our operating and capital requirements through at least twelve months from the issuance of this Quarterly Report on Form 10-Q.

We will need to raise significant additional capital to continue to fund the clinical trials for CRB-701, CRB-601 and CRB-913. We may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.

The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or all of our planned clinical trials.

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors, other than future royalty payments under license agreements discussed as follows:

*License Agreement with Jenrin*

Pursuant to the terms of the license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound we elect to develop based upon the achievement of specified development and regulatory milestones. In addition, we are obligated to pay Jenrin royalties in the mid, single digits based on net sales of any Licensed Products, as defined in the Jenrin License Agreement, subject to specified reductions. A $0.4 million milestone payment was achieved in the first quarter of 2025 associated with the progression into a clinical trial for CRB-913 and paid during the second quarter of 2025. The Company is obligated to pay Jenrin up to $18.0 million in additional potential milestone payments for further development of CRB-913.

The Jenrin License Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country. Each royalty term begins on the date of the first commercial sale of the licensed product in the applicable country and ends on the later of seven years from such first commercial sale or the expiration of the last to expire of the applicable patents in that country. The Jenrin License Agreement may be terminated earlier in specified situations, including termination for uncured material breach of the Jenrin License Agreement by either party, termination by Jenrin in specified circumstances, termination by Corbus with advance notice, and termination upon a party's insolvency or bankruptcy.

*License Agreement with UCSF*

Pursuant to the terms of the license agreement (the "UCSF License Agreement") with the Regents of the University of California, we are obligated to pay up to $150.8 million in remaining potential milestone payments based upon the achievement of specified development and regulatory milestones, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50.0 thousand for each new indication. In addition, we are obligated to pay royalties in the lower, single digits based on net sales of any Licensed Products, as defined in the UCSF License Agreement, and any diagnostic products and services.

The UCSF License Agreement will remain in effect until the expiration or abandonment of the last of the Patent Rights licensed. The Royalty Term is the duration of Patent Rights in that country covering the applicable Licensed Product or Licensed Services Sold in the country. The UCSF License Agreement may be terminated earlier in specified situations, including termination for material breach, termination by us with advance notice, and termination upon a party's bankruptcy.

------

*License Agreement with CSPC*

Pursuant to the terms of the license agreement with CSPC (the "CSPC License Agreement"), we are obligated to pay potential milestone payments to CSPC totaling up to $130.0 million based upon the achievement of specified development and regulatory milestones and $555.0 million in potential commercial milestone payments. In addition, we are obligated to pay CSPC royalties in the low, double digits based on net sales of any Licensed Products, as defined in the CSPC License Agreement.

The CSPC License Agreement will remain in effect on a Licensed Product and on a country-by-country basis, until the expiration of the Royalty Term of the Licensed Product in the country. The Royalty Term is the period beginning from the First Commercial Sale of the Licensed Product in the country until the later of the expiration of the last-to-expire Valid Claim in any Licensor Patent in the country that Covers the Licensed product, 10 years after the date of the First Commercial Sale in the country, or expiration of the Regulatory Exclusivity for the Licensed Product in the country. The CSPC License Agreement may be terminated earlier in specified situations, including termination for material breach, termination by Corbus with advance notice, and termination upon a party's bankruptcy.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Not Applicable.

**Item 4. Controls and Procedures.**

*Evaluation of Our Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our principal executive officer and our principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act, as amended) as of the end of the period covered by this report.

Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II — OTHER INFORMATION**

**Item 1. Legal Proceedings.**

We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

**Item 1A. Risk Factors.**

Except as set forth below, there have been no material changes in or additions to the risk factors included in our 2024 Annual Report.

***Adverse global conditions, including economic uncertainty, may negatively impact our financial results.***

Global conditions, dislocations in the financial markets, any negative financial impacts affecting U.S. as a result of tax reform or changes to existing trade agreements or tax conventions, may adversely impact our business.

In addition, the global macroeconomic environment could be negatively affected by, among other things, pandemics or epidemics, instability in global economic markets, increased U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability in the geopolitical environment as a result of military conflict and other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty and instability in local economies and in global financial markets.

Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs. In 2025, the United States announced tariffs on all foreign goods and individualized higher reciprocal tariffs on goods imported from certain countries. Tariffs could result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners' drug products, affect our and our collaboration partners' ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

*Director and Officer Trading Arrangements*

No directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the third quarter of 2025.

------

**Item 6. Exhibits.**

The exhibits listed below are filed or furnished as part of this Quarterly Report on Form 10-Q.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 3.1 | [<u>Amended and Restated Certificate of Incorporation of the Company, as amended (incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1595097/000095017023006469/crbp-ex3_1.htm) |
| 3.2 | [<u>Amended and Restated Bylaws of the Company (incorporated by reference to the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1595097/000095017023006469/crbp-ex3_2.htm) |
| 31.1 | [<u>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).\*</u>](crbp-ex31_1.htm) |
| 31.2 | [<u>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).\*</u>](crbp-ex31_2.htm) |
| 32.1 | [<u>Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).\*\*</u>](crbp-ex32_1.htm) |
| 32.2 | [<u>Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).\*\*</u>](crbp-ex32_2.htm) |
| 101.INS | Inline XBRL Instance Document.\* - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.\* |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 is formatted in iXBRL\* |

---

------

\* Filed herewith. <br> \*\* Furnished, not filed.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Corbus Pharmaceuticals Holdings, Inc.** | **Corbus Pharmaceuticals Holdings, Inc.** |
| *Date: November 12, 2025* | By: | */s/ Yuval Cohen* |
|  | Name:  | Yuval Cohen |
|  | Title: | *Chief Executive Officer* |
|  |  | *(Principal Executive Officer)* |
| *Date: November 12, 2025* | By: | */s/ Sean Moran* |
|  | Name: | Sean Moran |
|  | Title: | *Chief Financial Officer* |
|  |  | *(Principal Financial Officer and Chief Accounting Officer)* |

---

------

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT**

**TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Yuval Cohen, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2025 of Corbus Pharmaceuticals Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: November 12, 2025 |
| */s/ Yuval Cohen* |
| Yuval Cohen |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT**

**TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Sean M. Moran, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2025 of Corbus Pharmaceuticals Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: November 12, 2025 |
| */s/ Sean Moran*  |
| Sean Moran |
| Chief Financial Officer |
| (Principal Financial Officer and Chief Accounting Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**Certification of Chief Executive Officer Pursuant to**

**18 U.S.C. Section 1350, as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

This Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002. This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act and is not intended to be used for any other purpose. In connection with the accompanying Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the "Quarterly Report") of Corbus Pharmaceuticals Holdings, Inc. (the "Company"), the undersigned hereby certifies in his capacity as an officer of the Company that to such officer's knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
|  | By:  | */s/ Yuval Cohen*  |
| Dated: November 12, 2025 |  | Yuval Cohen |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**Certification of Chief Financial Officer Pursuant to**

**18 U.S.C. Section 1350, as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

This Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002. This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act and is not intended to be used for any other purpose. In connection with the accompanying Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, (the "Quarterly Report") of Corbus Pharmaceuticals Holdings, Inc. (the "Company"), the undersigned hereby certifies in his capacity as an officer of the Company that to such officer's knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
|  | By: | */s/ Sean Moran*  |
| Dated: November 12, 2025 |  | Sean Moran |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer and Chief Accounting Officer) |

---

------